Praxis nosedives as antidepressant effort collapses in PhII/III fail — layoffs to follow - Endpoints News

Praxis shares $PRAX are taking a tumble Monday after the company reported its lead depression drug failed a Phase II/III study, forcing a substantial pipeline reorganization and layoffs. The biotech said the program known as PRAX-114 missed the primary endpoi…

In an ongoing, 18-person study, every single patient that has completed treatment saw their rectal cancer completely disappear. None of them needed chemotherapy, radiation, or surgery — the combinat… [+556 chars]

full article...